fimasartan

02/01/2013 - "Safety and efficacy of fimasartan in patients with arterial hypertension (Safe-KanArb study): an open-label observational study."
05/01/2018 - "Areas covered: We reviewed data from clinical trials that investigated safety and efficacy of fimasartan in hypertension. "
02/01/2013 - "This was a large-scale, open-label observational study to determine the safety and efficacy of fimasartan in patients with hypertension. "
01/01/2022 - "Comparative efficacy and safety of fimasartan in patients with hypertension: A network meta-analysis of randomized controlled trials."
01/01/2018 - "Clinical characteristics and satisfaction with the fimasartan in Korean hypertensive patients: a prospective, cross-sectional and open-label, 8-week switching study (Kanarb-hypertension epidemiology medication satisfaction study; K-HEMS study)."

10/01/2017 - "Fimasartan is safe and effective in Mexican subjects with grade 1-2 essential hypertension."
09/01/2018 - "Safety and efficacy of fimasartan with essential hypertension patients in real world clinical practice: data from a post marketing surveillance in Korea."
10/01/2017 - "Safety and efficacy of fimasartan in Mexican patients with grade 1-2 essential hypertension."
09/01/2013 - "Ambulatory blood pressure response to once-daily fimasartan: an 8-week, multicenter, randomized, double-blind, active-comparator, parallel-group study in Korean patients with mild to moderate essential hypertension."
01/01/2020 - "This prospective, 12-month, observational study evaluated patients with essential hypertension (HTN) receiving ≥1 dose of fimasartan. "

03/15/2019 - "Fimasartan for Remodeling after Myocardial Infarction."
05/01/2019 - "Therapeutic Effect of Fimasartan in a Rat Model of Myocardial Infarction Evaluated by Cardiac Positron Emission Tomography with [18F]FPTP."
01/01/2015 - "Cardioprotective effect of fimasartan, a new angiotensin receptor blocker (ARB), was evaluated in a porcine model of acute myocardial infarction (MI). "
01/01/2015 - "Cardioprotective effect of fimasartan, a new angiotensin receptor blocker, in a porcine model of acute myocardial infarction."
01/01/2015 - "Fimasartan is a newly developed angiotensin receptor blocker, which may have protective effects during myocardial infarction or atherosclerosis. "

11/01/2018 - "We investigated the protective effects of pretreatment with fimasartan on ischemia-reperfusion injury (IRI) in a mouse model of ischemic renal damage. "
02/01/2022 - "Fimasartan ameliorates renal ischemia reperfusion injury via modulation of oxidative stress, inflammatory and apoptotic cascades in a rat model."
11/01/2018 - "Fimasartan attenuates renal ischemia-reperfusion injury by modulating inflammation-related apoptosis."
10/03/2013 - "Effects of the novel angiotensin II receptor type I antagonist, fimasartan on myocardial ischemia/reperfusion injury."

01/01/2019 - "This study suggests fimasartan could be an efficient strategy for reduction of atherosclerotic progression, with a decrease in immune response and systemic inflammation."
01/01/2015 - "We have demonstrated that long-term, low-dose fimasartan treatment improved outcomes after focal ischemia in the brain via a reduction of inflammation. "
03/15/2019 - "A microarray analysis revealed that the expression of genes related to the lipid metabolism and mitochondrial membrane ion transporters were upregulated, and those involved in fibrosis and inflammation were downregulated by fimasartan. "
11/01/2018 - "Fimasartan attenuates renal ischemia-reperfusion injury by modulating inflammation-related apoptosis."
01/01/2015 - "These results suggest that fimasartan has beneficial effects in reducing renal oxidative stress, inflammation, and fibrosis. "